[go: up one dir, main page]

CY1111061T1 - Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων - Google Patents

Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων

Info

Publication number
CY1111061T1
CY1111061T1 CY20101101192T CY101101192T CY1111061T1 CY 1111061 T1 CY1111061 T1 CY 1111061T1 CY 20101101192 T CY20101101192 T CY 20101101192T CY 101101192 T CY101101192 T CY 101101192T CY 1111061 T1 CY1111061 T1 CY 1111061T1
Authority
CY
Cyprus
Prior art keywords
hydrocyclic
lactama
inhibitions
unions
beta
Prior art date
Application number
CY20101101192T
Other languages
English (en)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Alan Rowlands
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel filed Critical Novexel
Publication of CY1111061T1 publication Critical patent/CY1111061T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αφορά την χρήση ενώσεων του τύπου (1) και των φαρμακευτικώς αποδεκτών αλάτων αυτών στην παρασκευή ενός φαρμάκου που προορίζεται για να αναστέλλεται η παραγωγή β-λακταμασών από τα παθογόνα βακτηρίδια.
CY20101101192T 2002-01-28 2010-12-23 Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων CY1111061T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP03709903A EP1480644B1 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
CY1111061T1 true CY1111061T1 (el) 2015-06-11

Family

ID=27619669

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20101101192T CY1111061T1 (el) 2002-01-28 2010-12-23 Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
CY20131100090T CY1114417T1 (el) 2002-01-28 2013-01-31 Ετεροκυκλικες ενωσεις, δραστικες ως αναστολεις των βητα-λακταμασων
CY2016042C CY2016042I2 (el) 2002-01-28 2016-12-06 Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20131100090T CY1114417T1 (el) 2002-01-28 2013-01-31 Ετεροκυκλικες ενωσεις, δραστικες ως αναστολεις των βητα-λακταμασων
CY2016042C CY2016042I2 (el) 2002-01-28 2016-12-06 Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων

Country Status (45)

Country Link
US (4) US7612087B2 (el)
EP (2) EP2279737B1 (el)
JP (1) JP4472346B2 (el)
KR (1) KR100979079B1 (el)
CN (3) CN101406471A (el)
AR (2) AR038234A1 (el)
AT (1) ATE484281T1 (el)
AU (1) AU2003214335B2 (el)
BE (1) BE2016C069I2 (el)
BR (1) BRPI0307267B8 (el)
CA (1) CA2474043C (el)
CL (1) CL2011000009A1 (el)
CO (1) CO5601014A2 (el)
CR (2) CR7387A (el)
CY (3) CY1111061T1 (el)
DE (1) DE60334527D1 (el)
DK (2) DK1480644T3 (el)
EA (1) EA007220B1 (el)
EC (1) ECSP045193A (el)
ES (2) ES2401855T3 (el)
FR (2) FR2835186B1 (el)
HK (2) HK1077205A1 (el)
HR (1) HRP20040686B1 (el)
HU (1) HUS1600055I1 (el)
IL (1) IL163167A (el)
JO (1) JO2646B1 (el)
LT (1) LTC1480644I2 (el)
MA (1) MA26351A1 (el)
MX (1) MXPA04006621A (el)
MY (1) MY140638A (el)
NL (1) NL300847I2 (el)
NO (2) NO335195B1 (el)
NZ (1) NZ533936A (el)
OA (1) OA12761A (el)
PE (1) PE20030969A1 (el)
PL (1) PL220725B1 (el)
PT (2) PT2279737E (el)
RS (1) RS52137B (el)
SI (2) SI1480644T1 (el)
TN (1) TNSN04137A1 (el)
TW (1) TWI293071B (el)
UA (1) UA80271C2 (el)
UY (1) UY27626A1 (el)
WO (1) WO2003063864A2 (el)
ZA (1) ZA200405607B (el)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
US8901293B2 (en) * 2005-12-07 2014-12-02 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
JP2010507681A (ja) * 2006-10-23 2010-03-11 アイアールエム・リミテッド・ライアビリティ・カンパニー カテプシンプロテアーゼ阻害剤
JP5323063B2 (ja) * 2007-05-31 2013-10-23 塩野義製薬株式会社 オキシイミノ化合物およびその使用
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) * 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
WO2009151152A1 (en) * 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
SMT202000248T1 (it) 2010-08-10 2020-07-08 Rempex Pharmaceuticals Inc Derivati di estere di acido boronico ciclico e relativi usi terapeutici
SG191320A1 (en) * 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
MY165730A (en) * 2011-06-17 2018-04-20 Pfizer Anti Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CA2833241C (en) * 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
MX349827B (es) * 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PL2857401T3 (pl) 2012-05-30 2020-02-28 Meiji Seika Pharma Co., Ltd. NOWY INHIBITOR ß–LAKTAMAZY I SPOSÓB JEGO WYTWARZANIA
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6329147B2 (ja) * 2012-08-25 2018-05-23 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
KR102239725B1 (ko) 2013-09-24 2021-04-12 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 제조법과 그의 중간체
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
AR097971A1 (es) 2013-10-08 2016-04-20 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
WO2015125031A1 (en) * 2014-02-20 2015-08-27 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US9963467B2 (en) 2014-05-19 2018-05-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
JP6700203B2 (ja) 2014-07-01 2020-05-27 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
PT3221313T (pt) 2014-11-17 2019-04-15 Entasis Therapeutics Ltd Terapia combinada para tratamento de infecções bacterianas resistentes
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3228620B1 (en) 2014-12-05 2020-09-02 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016177862A1 (en) * 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
KR20170131661A (ko) * 2015-09-16 2017-11-29 수안주 파마 코포레이션 리미티드 β-락타메이즈 억제제 및 이의 용도
AU2016332964A1 (en) 2015-10-02 2018-04-12 Legochem Biosciences, Inc. Compositions and methods for inhibiting beta-lactamase
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
MA46242A (fr) 2016-09-16 2019-07-24 Entasis Therapeutics Ltd Composés inhibiteurs de bêta-lactamase
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
CN110392684A (zh) 2017-02-06 2019-10-29 拜欧蒂姆公司 新型杂环化合物及其在预防或治疗细菌感染中的用途
KR102611447B1 (ko) 2017-05-08 2023-12-06 엔타시스 테라퓨틱스, 인크. 박테리아 감염을 치료하는 화합물 및 방법
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
CA3078627A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
CN115151544B (zh) * 2020-09-01 2024-08-16 宁夏农林科学院 β-内酰胺酶抑制剂及其制备
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
DE69016430T2 (de) 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
AU7844594A (en) 1993-09-29 1995-04-18 Barry Burns Ring-expanded nucleosides and nucleotides
CA2180263C (en) * 1993-12-29 2000-05-16 Harry R. Howard, Jr. Diazabicyclic neurokinin antagonists
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
AU715229B2 (en) * 1996-01-03 2000-01-20 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline and their use as antibacterials
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
WO1999052875A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
EP1091944A1 (en) 1998-06-30 2001-04-18 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ID29065A (id) 1998-12-18 2001-07-26 Schering Corp Penghambat-penghambat farnesil protein transferase
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US7179921B2 (en) 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
CN100563653C (zh) 2009-12-02
BR0307267A (pt) 2004-12-07
CN1655781A (zh) 2005-08-17
BE2016C069I2 (el) 2022-05-17
NO335195B1 (no) 2014-10-20
EA200400981A1 (ru) 2005-02-24
CN100482225C (zh) 2009-04-29
NO2016024I1 (no) 2016-12-15
FR16C1019I1 (fr) 2017-02-03
JP2005523897A (ja) 2005-08-11
CL2011000009A1 (es) 2011-03-25
FR2835186A1 (fr) 2003-08-01
BRPI0307267B1 (pt) 2016-02-10
CA2474043A1 (fr) 2003-08-07
DK1480644T3 (da) 2011-01-24
NL300847I2 (el) 2017-01-03
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
CN101406471A (zh) 2009-04-15
OA12761A (fr) 2006-07-04
ATE484281T1 (de) 2010-10-15
WO2003063864A2 (fr) 2003-08-07
TWI293071B (en) 2008-02-01
CA2474043C (fr) 2011-08-02
PT2279737E (pt) 2013-02-01
US20100048528A1 (en) 2010-02-25
ZA200405607B (en) 2005-09-28
RS52137B (en) 2012-08-31
DE60334527D1 (de) 2010-11-25
US20050020572A1 (en) 2005-01-27
US20110245254A1 (en) 2011-10-06
CN1994301A (zh) 2007-07-11
HUS1600055I1 (hu) 2017-01-30
FR2835186B1 (fr) 2006-10-20
ECSP045193A (es) 2004-08-27
WO2003063864A3 (fr) 2004-03-11
AR100790A2 (es) 2016-11-02
JO2646B1 (en) 2012-06-17
LTPA2016037I1 (lt) 2017-01-10
PL220725B1 (pl) 2015-12-31
CO5601014A2 (es) 2006-01-31
US20090215747A1 (en) 2009-08-27
AR038234A1 (es) 2005-01-05
NZ533936A (en) 2007-05-31
PL371601A1 (en) 2005-06-27
LTC1480644I2 (lt) 2018-09-10
YU65804A (sh) 2006-08-17
CY2016042I1 (el) 2017-03-15
HK1077205A1 (en) 2006-02-10
NO2016024I2 (no) 2016-12-15
HK1105864A1 (en) 2008-02-29
HRP20040686B1 (hr) 2013-02-28
MXPA04006621A (es) 2004-10-04
DK2279737T3 (da) 2013-02-11
UY27626A1 (es) 2003-08-29
MY140638A (en) 2010-01-15
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
BRPI0307267B8 (pt) 2021-05-25
SI1480644T1 (sl) 2011-03-31
ES2401855T3 (es) 2013-04-25
HRP20040686A2 (en) 2004-12-31
KR20040081473A (ko) 2004-09-21
US7612087B2 (en) 2009-11-03
CY1114417T1 (el) 2016-08-31
JP4472346B2 (ja) 2010-06-02
AU2003214335B2 (en) 2007-04-05
TNSN04137A1 (fr) 2007-03-12
FR16C1019I2 (fr) 2017-12-29
CR7387A (es) 2010-10-25
EP1480644B1 (fr) 2010-10-13
EP2279737A1 (fr) 2011-02-02
SI2279737T1 (sl) 2013-07-31
EA007220B1 (ru) 2006-08-25
EP2279737B1 (fr) 2012-10-31
ES2356813T3 (es) 2011-04-13
NO20043587L (no) 2004-08-27
UA80271C2 (uk) 2007-09-10
MA26351A1 (fr) 2004-10-01
IL163167A (en) 2010-04-15
PT1480644E (pt) 2011-01-17
CY2016042I2 (el) 2017-03-15
KR100979079B1 (ko) 2010-08-31

Similar Documents

Publication Publication Date Title
CY1111061T1 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NO2011026I1 (no) Eribulin og farmasøytisk akseptable salter derav
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
NO20065904L (no) Terapeutiske forbindelser
YU69902A (sh) Novi derivati piperazina
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0102055D0 (sv) New Compounds
SE0102440D0 (sv) New compound
ECSP055844A (es) Nuevos compuestos triciclicos
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
NO20030931L (no) Cefalosporin-antibiotika og prodruger derav
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
SE0102057D0 (sv) New Salts I
ATE295845T1 (de) Prucaloprid-n-oxid
EA200401082A1 (ru) Новые соединения бензоиндолина, способ их получения и фармацевтические композиции, которые их содержат
BR122015020406B8 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas